# FIGHT-302 (NCT03656536)

> A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03656536
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Incyte Corporation
- Conditions: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
- Interventions: Pemigatinib; Gemcitabine; Cisplatin
- Enrollment: 167
- Primary outcome: Randomized Treatment Period: Progression-free Survival (PFS)
- Primary outcome: Randomized Treatment Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time
- Primary outcome: Transition Period: PFS
- Primary outcome: Transition Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time

## Commentary we found

- X threads: 18
- YouTube: 5
- Podcasts: 2
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=fight-302-nct03656536

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03656536", "email": "<work email>"}; the inbox owner confirms by the emailed link.